CelluTarget · Multifocal Motor Neuropathy · Treatments
✓ Standard of Care

Deutetrabenazine (Austedo / Austedo XR)

Teva Pharmaceuticals ↗
2
Evidence entries
0
Clinical trials
2
High-confidence findings
Overview
Treatment Details
Mechanism of Action
A deuterated form of tetrabenazine — substituting deuterium for hydrogen at key positions — that extends the drug's half-life, allowing less frequent dosing and more stable plasma levels with fewer peak-related side effects. Reversibly inhibits VMAT2 to reduce chorea. FDA-approved 2017 (twice-daily), with a once-daily extended-release formulation (Austedo XR) approved for both HD chorea and tardive dyskinesia.
Dosing Notes
Twice-daily Austedo titrated from 6 mg/day; once-daily Austedo XR available in 6, 12, and 24 mg strengths.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
The First-HD trial (NCT01795859) showed a mean Total Maximal Chorea score decrease of 4.5 points versus placebo. Long-term open-label extension and post hoc analyses of the ARM-TD/AIM-TD studies confirmed sustained improvement and good tolerability over 3 years. Once-daily extended-release Austedo XR was approved to reduce pill burden versus the original twice-daily formulation.
Verified Jul 2026
Institutional Research
FDA Approves Extended-Release Deutetrabenazine for Huntington Disease Chorea
Published June 2026
View source ↗
Compared with tetrabenazine, deutetrabenazine has a more favorable safety profile, with sedation/somnolence reported in approximately 11% of patients versus 31% for tetrabenazine.
Verified Jul 2026
Peer Reviewed
Treatment Considerations With VMAT2 Inhibitors for Chorea in Huntington Disease
Published January 2026
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.
Deutetrabenazine (Austedo / Austedo XR) for MMN — Evidence & Clinical Trials | CelluTarget